Business
MedMira Strengthens US Patent Protection with New Filings and Continued Examination
HALIFAX, Oct. 21 /CNW/ - MedMira Inc., ("MedMira") (TSX Venture: MIR, NASDAQ: MMIRF), a developer...
About this update from Medmira Inc.
[{"type":"text","content":"\n\n\n\nHALIFAX, Oct. 21 /CNW/ - MedMira Inc., ("MedMira") (TSX Venture: MIR,\nNASDAQ: MMIRF), a developer and marketer of rapid diagnostics, announced today\nthat it is broadening its US patent portfolio with new filings related to the\nCompany's rapid flow-through technology, the core innovation behind its rapid\ndiagnostics. In order to strengthen its overall IP position, the Company has\nalso filed for continued examination on its original US patent application\nthat was allowed in July 2008.\n\n\n"We believe that our technology is one of our Company's most valuable\nassets and as such we are taking further steps to strengthen the IP around it,\nas we move forward with licensing and partnership opportunities. Additional IP\nwas identified during our review and analysis of our rapid flow-through\ntechnology and we are now working with our external team to prepare and file\npatent applications to protect it," said Dr. Neeraj Vats, VP of Technology &\nIntellectual Property, MedMira Inc. "We will also be filing a Request for\nContinued Examination in order to strengthen our original US patent\napplication, which received a Notice of Allowance from the USPTO earlier this\nyear."\n\n\nAbout MedMira\n\n\nMedMira is a leading developer and manufacturer of flow-through rapid\ndiagnostics. The company's tests provide hospitals, labs, clinics and\nindividuals with reliable, rapid diagnosis for diseases such as HIV and\nhepatitis C in just three minutes. The company's tests are sold under the\nReveal(R), MiraWell(R), MiraCare(TM) and Multiplo(TM) brands in global\nmarkets. MedMira's rapid HIV test is the only one in the world to achieve\nregulatory approvals in Canada, the United States, China and the European\nUnion. MedMira's corporate offices and manufacturing facilities are located in\nHalifax, Nova Scotia, Canada. For more information visit MedMira's website at\nwww.medmira.com.\n\n\nThis news release contains forward-looking statements, which involve risk\nand uncertainties and reflect the company's current expectation regarding\nfuture events. Actual events could materially differ from those projected\nherein and depend on a number of factors including, but not limited to,\nchanging market conditions, successful and timely completion of clinical\nstudies, uncertainties related to the regulatory a...